AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11344343 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol plus low-dose fluticasone (42 microg of salmeterol and 88 microg of FP)
Number of subjects: 925
Study 11344343 — intervention group
Group type: COMPARATOR
Intervention: Higher-dose fluticasone (220 microg)
Number of subjects: 925
Study 11344343 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol plus low-dose FP
Number of subjects: 925
Study 9022580 — intervention group
Group type: EXPERIMENTAL
Intervention: T1-weighted axial and coronal images with an axial FSE T2-weighted sequence
Number of subjects: 0
Study 9022580 — intervention group
Group type: COMPARATOR
Intervention: Enhanced T1 fat suppressed sequence
Number of subjects: 0
Study 7937520 — intervention group
Group type: EXPERIMENTAL
Intervention: R(−)ibuprofen (intravenously infused as a racemic mixture)
Number of subjects: 12
Study 7937520 — intervention group
Group type: EXPERIMENTAL
Intervention: R(−)ibuprofen (intravenously infused alone)
Number of subjects: 12
Study 7937520 — intervention group
Group type: EXPERIMENTAL
Intervention: S(+)ibuprofen (dosed as S(+)ibuprofen)
Number of subjects: 12
Study 7937520 — intervention group
Group type: EXPERIMENTAL
Intervention: R(−)ibuprofen (concurrent administration with S(+)ibuprofen)
Number of subjects: 12
Study 7937520 — intervention group
Group type: EXPERIMENTAL
Intervention: R(−)ibuprofen (intravenous dose)
Number of subjects: 12
Study 7937520 — intervention group
Group type: EXPERIMENTAL
Intervention: R(−)ibuprofen lysinate (oral dose)
Number of subjects: 12
Study 7937520 — intervention group
Group type: EXPERIMENTAL
Intervention: S(+)ibuprofen
Number of subjects: 12
Study 7937520 — intervention group
Group type: EXPERIMENTAL
Intervention: R(−)ibuprofen (dosed alone)
Number of subjects: 12
Study 29471679 — intervention group
Group type: EXPERIMENTAL
Intervention: 70 mg erenumab
Number of subjects: 577
Study 29471679 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 577
Study 27103412 — intervention group
Group type: EXPERIMENTAL
Intervention: Partnered conditions (partner‐ingroup and partner‐outgroup)
Number of subjects: 96
Study 27103412 — intervention group
Group type: EXPERIMENTAL
Intervention: Partner‐ingroup ('Us')
Number of subjects: 96
Study 27103412 — intervention group
Group type: EXPERIMENTAL
Intervention: Partner‐outgroup ('Them')
Number of subjects: 96
Study 25071111 — intervention group
Group type: COMPARATOR
Intervention: Patient navigation (navigated participants) for antiestrogen therapy
Number of subjects: 761
Study 25071111 — intervention group
Group type: COMPARATOR
Intervention: Patient navigation (navigated participants) for radiation therapy
Number of subjects: 761
Study 22215243 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic paraesophageal hernia repair (LPEHR)
Number of subjects: 108
Study 20113387 — intervention group
Group type: EXPERIMENTAL
Intervention: Red grape juice
Number of subjects: 10
Study 20113387 — intervention group
Group type: EXPERIMENTAL
Intervention: Red grape juice plus alcohol (12% v/v)
Number of subjects: 10
Study 20113387 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 10
Study 18204347 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex
Number of subjects: 85
Study 18204347 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 17011849 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic contour tonometry PASCAL (DCT‐PASCAL)
Number of subjects: 107
Study 17011849 — intervention group
Group type: COMPARATOR
Intervention: Goldmann applanation tonometry (GAT)
Number of subjects: 107
Study 15058555 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice application
Number of subjects: 36
Study 15058555 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ice application)
Number of subjects: 36
Study 11034230 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation in a simulated environment (Easy Street) for 16 weeks
Number of subjects: 88
Study 11034230 — intervention group
Group type: COMPARATOR
Intervention: Rehabilitation in a gymnasium setting for 16 weeks
Number of subjects: 88
Study 8971313 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular ketorolac 30 mg
Number of subjects: 66
Study 8971313 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin 100 mg
Number of subjects: 66
Study 8971313 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin 200 mg
Number of subjects: 66
Study 1485176 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron 32 mg IV x 1
Number of subjects: 618
Study 1485176 — intervention group
Group type: COMPARATOR
Intervention: ondansetron 8 mg IV x 1
Number of subjects: 618
Study 1485176 — intervention group
Group type: COMPARATOR
Intervention: ondansetron 0.15 mg/kg IV every 4 hours x 3
Number of subjects: 618
Study 6442440 — intervention group
Group type: COMPARATOR
Intervention: Bupropion (Wellbutrin)
Number of subjects: 0
Study 6442440 — intervention group
Group type: COMPARATOR
Intervention: Alprazolam (Xanax)
Number of subjects: 0
Study 30019939 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol/Glycopyrronium
Number of subjects: 457
Study 30019939 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol/Fluticasone
Number of subjects: 457
Study 30019939 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom-defined (EXACT) events
Number of subjects: 457
Study 30149537 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic inflammation at 6 weeks of age
Number of subjects: 590
Study 30149537 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of IGF-1 at 6 weeks
Number of subjects: 590
Study 30149537 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of IGF-1 at 6 months
Number of subjects: 590
Study 30149537 — intervention group
Group type: COMPARATOR
Intervention: Overall incidence of stunting
Number of subjects: 590
Study 26877217 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Imagery Training (FIT)
Number of subjects: 45
Study 26877217 — intervention group
Group type: COMPARATOR
Intervention: Delayed group (control)
Number of subjects: 45
Study 26877217 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (FIT and control)
Number of subjects: 45
Study 23338665 — intervention group
Group type: EXPERIMENTAL
Intervention: Anatomic single-bundle ACL reconstruction
Number of subjects: 66
Study 23338665 — intervention group
Group type: EXPERIMENTAL
Intervention: Anatomic double-bundle ACL reconstruction
Number of subjects: 66
Study 22646319 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated Learning Environment (SLE) Model 1: 1 week in SLE followed by 3 weeks in clinical immersion
Number of subjects: 370
Study 22646319 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated Learning Environment (SLE) Model 2: Training in SLE in parallel with clinical immersion during the first 2 weeks of the 4-week placement
Number of subjects: 370
Study 22646319 — intervention group
Group type: COMPARATOR
Intervention: Traditional clinical immersion (4 weeks)
Number of subjects: 370
Study 20210996 — intervention group
Group type: EXPERIMENTAL
Intervention: Monodisciplinary chiropractic care
Number of subjects: 200
Study 20210996 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary integrative care
Number of subjects: 200
Study 18156661 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple bouts of resistance exercise (20 sets of 15 repetitions of 5 different exercises at 30-40% of 1-repetition maximum)
Number of subjects: 24
Study 18156661 — intervention group
Group type: COMPARATOR
Intervention: Control (inactive, no exercise)
Number of subjects: 24
Study 18156661 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple bouts of resistance exercise
Number of subjects: 24
Study 16335904 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (8-week administration)
Number of subjects: 32
Study 16335904 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 32
Study 11949644 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 2 mg.kg(‐1)
Number of subjects: 150
Study 11949644 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 1 mg.kg(‐1)
Number of subjects: 150
Study 11949644 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline (control group)
Number of subjects: 150
Study 9579457 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal glyceryl trinitrate
Number of subjects: 26
Study 9579457 — intervention group
Group type: COMPARATOR
Intervention: Intravenous albuterol
Number of subjects: 26
Study 9579457 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 26
Study 8563679 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy resistance training (12 sets of 6‐ to 12‐RM elbow flexion exercises)
Number of subjects: 6
Study 8563679 — intervention group
Group type: COMPARATOR
Intervention: Control arm (opposite arm not exercised)
Number of subjects: 6
Study 2692666 — intervention group
Group type: EXPERIMENTAL
Intervention: iohexol
Number of subjects: 90
Study 2692666 — intervention group
Group type: COMPARATOR
Intervention: meglumine metrizoate
Number of subjects: 90
Study 2692666 — intervention group
Group type: EXPERIMENTAL
Intervention: diabetic nephropathy
Number of subjects: 90
Study 319259 — intervention group
Group type: EXPERIMENTAL
Intervention: vented urinary drainage system
Number of subjects: 506
Study 319259 — intervention group
Group type: COMPARATOR
Intervention: non-vented urinary drainage system
Number of subjects: 506
Study 30965138 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiotepa-Busulfan conditioning followed by autologous stem cell transplantation (TBu/ASCT)
Number of subjects: 64
Study 30965138 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose methotrexate/cytarabine-based induction followed by ASCT
Number of subjects: 64
Study 30965138 — intervention group
Group type: EXPERIMENTAL
Intervention: HDMTX-based protocol for transplantation-ineligible patients
Number of subjects: 64
Study 27986352 — intervention group
Group type: EXPERIMENTAL
Intervention: LHW+Print
Number of subjects: 725
Study 27986352 — intervention group
Group type: COMPARATOR
Intervention: Print
Number of subjects: 725
Study 25497751 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 60
Study 25497751 — intervention group
Group type: COMPARATOR
Intervention: Magnesium sulfate
Number of subjects: 60
Study 23587090 — intervention group
Group type: EXPERIMENTAL
Intervention: Text message reminder system for oral glucose tolerance test at 6 weeks postpartum, with further reminders at 3 months and 6 months if they do not respond to indicate test completion.
Number of subjects: 276
Study 23587090 — intervention group
Group type: COMPARATOR
Intervention: Single text message reminder at 6 months postpartum.
Number of subjects: 276
Study 21323292 — intervention group
Group type: EXPERIMENTAL
Intervention: Retro-tubercle opening-wedge high tibial osteotomy
Number of subjects: 72
Study 21323292 — intervention group
Group type: COMPARATOR
Intervention: Medial opening-wedge osteotomy
Number of subjects: 72
Study 20141011 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol (n = 35)
Number of subjects: 67
Study 20141011 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol (n = 32)
Number of subjects: 67
Study 20141011 — intervention group
Group type: COMPARATOR
Intervention: Control group (BAB not included in guidelines)
Number of subjects: 67
Study 16942629 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea (HU)
Number of subjects: 299
Study 16942629 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 299
Study 12878366 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide SR 1.5 mg once daily for 3 months
Number of subjects: 64
Study 12878366 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 10868557 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination hydrocodone 7.5 mg and ibuprofen 200 mg
Number of subjects: 120
Study 10868557 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination oxycodone 5 mg and acetaminophen 325 mg
Number of subjects: 120
Study 10868557 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 9200361 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 days of erythromycin estolate (40 mg/kg/d; maximum dose 1 g/d)
Number of subjects: 168
Study 9200361 — intervention group
Group type: COMPARATOR
Intervention: 14 days of erythromycin estolate (40 mg/kg/d; maximum dose 1 g/d)
Number of subjects: 168
Study 1443486 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous infiltration with 1% lignocaine
Number of subjects: 0
Study 1443486 — intervention group
Group type: COMPARATOR
Intervention: No local anaesthetic
Number of subjects: 0
Study 3026006 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulbactam (0.5 g) plus ampicillin (1 g)
Number of subjects: 285
Study 3026006 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 285
Study 31329985 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy-related tweets
Number of subjects: 1000
Study 29161214 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component sun protection intervention (use of clothing, hats, shade, sunscreen application and reapplication)
Number of subjects: 3523
Study 26488833 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging intervention (daily texts for adherence and weekly for symptoms for 21-28 days)
Number of subjects: 80
Study 26488833 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging intervention
Number of subjects: 80
Study 23085392 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental Intervention (EI)
Number of subjects: 91
Study 23085392 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 91
Study 21993022 — intervention group
Group type: EXPERIMENTAL
Intervention: SuperSlow resistance training (SRT)
Number of subjects: 35
Study 21993022 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional resistance training (TRT)
Number of subjects: 35
Study 21993022 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 35
Study 18305998 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical treatment with T4
Number of subjects: 0
Study 18305998 — intervention group
Group type: EXPERIMENTAL
Intervention: Total thyroidectomy
Number of subjects: 0
Study 18305998 — intervention group
Group type: COMPARATOR
Intervention: Subtotal thyroidectomy
Number of subjects: 0
Study 18305998 — intervention group
Group type: COMPARATOR
Intervention: Less extensive resections
Number of subjects: 0
Study 18305998 — intervention group
Group type: COMPARATOR
Intervention: Less-than-total thyroidectomy
Number of subjects: 0
Study 18305998 — intervention group
Group type: COMPARATOR
Intervention: Less extensive operations
Number of subjects: 0
Study 18305998 — intervention group
Group type: EXPERIMENTAL
Intervention: Redo surgery
Number of subjects: 0
Study 18305998 — intervention group
Group type: COMPARATOR
Intervention: Initial operations
Number of subjects: 0
Study 18305998 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative TSH suppression
Number of subjects: 0
Study 16432347 — intervention group
Group type: EXPERIMENTAL
Intervention: Early enteral nutrition
Number of subjects: 0
Study 16432347 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary cholecystectomy
Number of subjects: 0
Study 16432347 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency endoscopic papillotomy followed by interval cholecystectomy
Number of subjects: 0
Study 16432347 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem or meropenem prophylaxis
Number of subjects: 0
Study 16432347 — intervention group
Group type: COMPARATOR
Intervention: Surgery for sterile necrosis
Number of subjects: 0
Study 16432347 — intervention group
Group type: COMPARATOR
Intervention: Immediate surgery for infected necrosis
Number of subjects: 0
Study 16432347 — intervention group
Group type: COMPARATOR
Intervention: Early necrosectomy
Number of subjects: 0
Study 16432347 — intervention group
Group type: EXPERIMENTAL
Intervention: Single necrosectomy with postoperative lavage
Number of subjects: 0
Study 12628877 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral azithromycin, 500 mg on day 1 and 250 mg per day for days 2 to 5
Number of subjects: 235
Study 12628877 — intervention group
Group type: COMPARATOR
Intervention: Oral levofloxacin, 500 mg q24h for 7 days
Number of subjects: 235
Study 11387366 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose therapy and autologous stem-cell transplantation (ASCT)
Number of subjects: 119
Study 11387366 — intervention group
Group type: COMPARATOR
Intervention: Conventional consolidation/maintenance chemotherapy (CC)
Number of subjects: 119
Study 9403744 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of furosemide
Number of subjects: 33
Study 9403744 — intervention group
Group type: COMPARATOR
Intervention: Intermittent bolus of furosemide
Number of subjects: 33
Study 8353025 — intervention group
Group type: EXPERIMENTAL
Intervention: High NaCl intake (240 mmol of NaCl/day for 15 days)
Number of subjects: 28
Study 8353025 — intervention group
Group type: COMPARATOR
Intervention: Low NaCl intake (40 mmol of NaCl/day for 15 days)
Number of subjects: 28
Study 3312701 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral TA-064 (20 mg)
Number of subjects: 8
Study 3312701 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dobutamine (5 micrograms/kg/min)
Number of subjects: 8
Study 3312701 — intervention group
Group type: COMPARATOR
Intervention: Control period (pre-dobutamine and pre-TA-064)
Number of subjects: 8
Study 30376834 — intervention group
Group type: EXPERIMENTAL
Intervention: Structural intervention including recruiting vulnerable young women to apply for government support programs, making support programs more accessible, and generating an enabling environment through an audio-drama edutainment program.
Number of subjects: 10
Study 30376834 — intervention group
Group type: COMPARATOR
Intervention: Control group (second-wave districts without the structural interventions).
Number of subjects: 10
Study 26906023 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily use of an antiretroviral tablet (tenofovir or Truvada)
Number of subjects: 5029
Study 26906023 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily use of tenofovir gel
Number of subjects: 5029
Study 26906023 — intervention group
Group type: EXPERIMENTAL
Intervention: Active products (tenofovir or Truvada)
Number of subjects: 5029
Study 26906023 — intervention group
Group type: COMPARATOR
Intervention: Routine follow-up visits
Number of subjects: 5029
Study 26906023 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial termination visit
Number of subjects: 5029
Study 25572426 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-paced, 48-week walking programme
Number of subjects: 386
Study 25572426 — intervention group
Group type: COMPARATOR
Intervention: Health information unrelated to falls (Control)
Number of subjects: 386
Study 22847712 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery-focused pre-diagnostic wellbeing assessment and counselling, diagnostic consultation with written feedback and post-diagnostic support over 6 months
Number of subjects: 34
Study 22847712 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 34
Study 21255959 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance abuse treatment (n = 113)
Number of subjects: 240
Study 21255959 — intervention group
Group type: COMPARATOR
Intervention: No substance abuse treatment (n = 127)
Number of subjects: 240
Study 19594274 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based intervention using a train-the-trainers model
Number of subjects: 0
Study 16798184 — intervention group
Group type: EXPERIMENTAL
Intervention: IABP-induced pulsatile cardiopulmonary bypass (group B)
Number of subjects: 50
Study 16798184 — intervention group
Group type: COMPARATOR
Intervention: Nonpulsatile cardiopulmonary bypass (group A)
Number of subjects: 50
Study 15769683 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic atraumatic coronary artery bypass (endo‐ACAB)
Number of subjects: 58
Study 15769683 — intervention group
Group type: COMPARATOR
Intervention: Sternotomy (control)
Number of subjects: 58
Study 10681321 — intervention group
Group type: EXPERIMENTAL
Intervention: DZ-2640 25 mg
Number of subjects: 6
Study 10681321 — intervention group
Group type: EXPERIMENTAL
Intervention: DZ-2640 400 mg
Number of subjects: 6
Study 10681321 — intervention group
Group type: EXPERIMENTAL
Intervention: DZ-2640 100 mg (fasted state)
Number of subjects: 6
Study 10681321 — intervention group
Group type: EXPERIMENTAL
Intervention: DZ-2640 100 mg (fed state)
Number of subjects: 6
Study 10681321 — intervention group
Group type: EXPERIMENTAL
Intervention: DZ-2640 (all doses)
Number of subjects: 6
Study 9316463 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat (200 mg) with a pure fat meal (10% Intralipid)
Number of subjects: 9
Study 9316463 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat (200 mg) with a meal containing free fatty acids
Number of subjects: 9
Study 9316463 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat (200 mg) with an albumin-glucose meal
Number of subjects: 9
Study 9316463 — intervention group
Group type: COMPARATOR
Intervention: Placebo with a pure fat meal (10% Intralipid)
Number of subjects: 9
Study 9316463 — intervention group
Group type: COMPARATOR
Intervention: Placebo with a meal containing free fatty acids
Number of subjects: 9
Study 9316463 — intervention group
Group type: COMPARATOR
Intervention: Placebo with an albumin-glucose meal
Number of subjects: 9
Study 8420767 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin adhesive (0.8‐1.4 ml) injected after fine needle puncture
Number of subjects: 60
Study 8420767 — intervention group
Group type: COMPARATOR
Intervention: Fine needle puncture only
Number of subjects: 60
Study 2891731 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 24
Study 2891731 — intervention group
Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 24
Study 29940390 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to positive NRT sentiment (mean exposure = 6.5 ± 14.7, mean sentiment = 5.4 ± 0.8) among participants who did not receive free NRT.
Number of subjects: 3297
Study 29940390 — intervention group
Group type: COMPARATOR
Intervention: Participants who received free NRT.
Number of subjects: 3297
Study 27778316 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive care management services
Number of subjects: 483
Study 27778316 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 483
Study 24026632 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel intervention for hazardous and harmful alcohol consumption
Number of subjects: 0